Entries |
Document | Title | Date |
20080221129 | New compounds - The present invention relates to compounds of the formula (I): | 09-11-2008 |
20080221130 | Fungicidal 5-Methyl-6-Phenylpyrazolopyrimidin-7-Ylamines - 5-Methyl-6-phenylpyrazolopyrimidin-7-ylamines of the formula I | 09-11-2008 |
20080262000 | 5-Alkoxyalkyl-6-alkyl-7-Aminoazolopyrimidines, Process for Their Preparation, Their Use for Controlling Harmful Fungi, and Compositions Comprising Them - 5-Alkoxyalkyl-6-alkyl-7-aminoazolopyrimidines of the formula I | 10-23-2008 |
20080287463 | Pyrazolopyrimidines - Pyrazolopyrimidines of the formula | 11-20-2008 |
20080300263 | Pyrazolo [1,5-a] pyrimidine compounds and pharmaceutical compositions containing them - The present invention relates to certain pyrazolo[1,5a]pyrimidine compounds, to processes for their preparation, compositions comprising them and methods of using them. The compounds are useful in the treatment of cancer. Novel screening methods are also provided. | 12-04-2008 |
20080306092 | Pyrazolo [1,5-Alpha] Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists - The present invention generally relates to the polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine. The present invention also relates to pharmaceutical compositions comprising the same and methods of using the same. | 12-11-2008 |
20090062312 | DEUTERIUM-ENRICHED INDIPLON - The present application describes deuterium-enriched indiplon, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090076034 | DEUTERIUM-ENRICHED BMS-690514 - The present application describes deuterium-enriched BMS-690514, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090176809 | RAF INHIBITOR COMPOUNDS AND METHODS - Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 07-09-2009 |
20090192175 | INSECTICIDAL COMPOUNDS - Novel heteroaromatic compounds of formula (I): wherein A | 07-30-2009 |
20090264448 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS - The invention provides novel pyrazolo[1,5-a]pyrimidines which are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation. | 10-22-2009 |
20100087451 | POLYMORPH B OF N--N-METHYL-ACETAMIDE - The present invention relates to a novel polymorph of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide, processes for its preparation, its use as a medicament, its use in the manufacture of a medicament, and pharmaceutical compositions comprising the novel polymorph. | 04-08-2010 |
20100093760 | METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE CELL SIGNALING AND METHODS EMPLOYING SUCH COMPOUNDS - The invention provides methods for identifying compounds that modulate cell signaling, as well as therapeutic methods that employ such compounds. | 04-15-2010 |
20100093761 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. | 04-15-2010 |
20100137339 | AMORPHOUS FORM OF N--N-METHYL-ACETAMIDE - The present invention relates to an amorphous form of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide, methods for its preparation, its use as a therapeutically active agent and pharmaceutical compositions comprising the novel form. | 06-03-2010 |
20100324073 | Pyrazolo [1,5-A] Pyrimidine Compounds - This invention relates generally to pyrazolo[1,5- | 12-23-2010 |
20100331347 | (EN) 3-SULFONYL-PYRAZOLO[1,5-A] PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF - The present invention relates to novel substituted 3-(arylsulfonyl)pyrazolo[1,5-a]pyrimidines of general formula 1 pharmaceutically acceptable salts and/or hydrates, to novel serotonin 5-HT | 12-30-2010 |
20110071166 | MEDICINE CONSISTING OF CONCOMITANT USE OR COMBINATION OF DPP-IV INHIBITOR AND OTHER DIABETIC MEDICINE - The problem to be solved by the present invention is to provide a medicine which is excellent in the treatment of type 2 diabetes, diabetic complications or impaired glucose tolerance. The present invention provides a medicine characterized in that a compound represented by the following general formula (I), a salt thereof, or a solvate thereof, and at least one kind of other diabetic medicine: | 03-24-2011 |
20110224234 | Polymorph B of N--N-methyl-acetamide - The present invention relates to a method of treating anxiety, epilepsy, sleep disorders, and insomnia, for inducing sedation-hypnosis, anesthesia, and muscle relaxation, and for modulating the necessary time to induce sleep and its duration, which comprises administering a therapeutically effective amount of Polymorph B of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-N-methyl-acetamide characterized by a powder X-Ray diffraction pattern containing specific peaks at 2θ=7.1° (±0.1°) and 21.4° (±0.1°) to a patient in need thereof. | 09-15-2011 |
20110294832 | FUSED RING COMPOUND AND USE THEREOF - Provided is a novel compound represented by the following formula | 12-01-2011 |
20120015962 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS - Compounds of the formula I or II: | 01-19-2012 |
20120041002 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS - The present invention relates to compounds of formula (I) | 02-16-2012 |
20120122888 | Potassium Channel Modulators - Disclosed herein are KCNQ potassium channels modulators of formula (I) | 05-17-2012 |
20120283274 | CRYSTALLINE FORMS OF SUBSTITUTED PYRAZOLOPYRIMIDINES - The present invention relates to novel co-crystals of pyrazolopyrimidines and a co-crystal former, wherein the co-crystal former is an organic carboxylic acid, preferably selected from the group of gentisic acid, succinic acid and xinafoic acid. | 11-08-2012 |
20120302585 | INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE - The present disclosure describes inhibitors of fatty acid uptake and methods of using such inhibitors. Specifically, the present disclosure describes inhibitors with specificity for FATP2. | 11-29-2012 |
20120309772 | INHIBITORS OF FATTY ACID UPTAKE AND METHODS OF USE - The present disclosure describes inhibitors of fatty acid uptake and methods of using such inhibitors. Specifically, the present disclosure describes inhibitors with specificity for FATP2. | 12-06-2012 |
20130102620 | PYRAZOLOPYRIMIDINE DERIVATIVE - The invention provides a pyrazolopyrimidine derivative of formula (I), wherein, for example, R | 04-25-2013 |
20130137707 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS - The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. | 05-30-2013 |
20130203777 | Identification of Stabilizers of Multimeric Proteins - Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and therby decreasing aggegate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein. | 08-08-2013 |
20130210838 | PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS - The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included. | 08-15-2013 |
20130210839 | FUSED AMINODIHYDROPYRIMIDINE DERIVATIVE - The present invention provides, for example, the following compound: | 08-15-2013 |
20130331401 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates - The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (I) wherein R, R | 12-12-2013 |
20140038988 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD - The present invention relates to novel heterocyclically fused diaryldihydropyrimidine derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system. | 02-06-2014 |
20140038989 | TETRAHYDROPYRAZOLO [1,5-A] PYRIMIDINE AS ANTI-TUBERCULOSIS COMPOUNDS - A compound of Formula (I) or a pharmaceutically acceptable salt thereof: | 02-06-2014 |
20140073653 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to compounds of formula IVA, formula IVB, or formula IVC, useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators. | 03-13-2014 |
20140155416 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS - There is provided a calcium receptor modulator comprising a compound of the formula (I): | 06-05-2014 |
20140288093 | TREATMENT OF PROTEINOPATHIES - The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore demonstrates the surprising applicability of such strategies in the treatment and/or prophylaxis of certain proteinopathies. Among other things, the present invention provides methods and compositions for the treatment and/or prophylaxis of proteinopathies other than lysosomal storage diseases through lysosomal activation. In particular, the present disclosure provides methods and compositions for the treatment and/or prophylaxis of neurodegenerative proteinopathies, and in particular those associated with accumulation of α-synuclein. The present disclosure specifically provides methods and compositions for the treatment and/or prophylaxis of Parkinson's disease. | 09-25-2014 |
20140288094 | PYRAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS - This invention relates to pyrazolopyridyl compounds of the structural formula: | 09-25-2014 |
20140315928 | SUBSTITUTED AMIDE COMPOUNDS - The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. | 10-23-2014 |
20150051227 | PREDICTIVE BIOMARKER USEFUL FOR CANCER THERAPY MEDIATED BY A CDK INHIBITOR - The present invention provides a predictive biomarker whose expression level is useful for identifying patients responsive to a therapeutically effective dose of a CDK inhibitor. In one embodiment of the invention, the predictive biomarker is the ratio of MCL-1 to BCL-xL (MCL-1:BCL-xL ratio) and the CDK inhibitor is SCH 927965 (Dinaciclib). | 02-19-2015 |
20150126531 | COMPOSITIONS AND METHODS FOR INCREASING NEUROTROPHIC PEPTIDES - A pharmaceutical composition is provided which includes a pharmaceutically acceptable excipient and a pharmaceutically and physically acceptable amount of a compound selected from the group consisting of Chemical Formulas I-IV as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods of increasing a level of a defined neurotrophic peptide in an organism or tissue comprising the administration of a pharmaceutically and physically acceptable amount of one or more of the compositions described above, and a method for treating a neurodegenerative disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim | 05-07-2015 |
20150306102 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS AKT KINASE INHIBITORS - Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals. | 10-29-2015 |
20160046617 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN - Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I: | 02-18-2016 |
20160058768 | SUBSTITUTED AMIDE COMPOUNDS - The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. | 03-03-2016 |
20160068534 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE - The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4 | 03-10-2016 |
20160102095 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVE AND USE OF ANTI-TUMOR THEREOF - The present invention relates to a pyrazolo[1,5-a]pyrimidine derivative of general formula 1 and a pharmaceutically acceptable salt thereof. The present invention also relates to use of compounds of formula 1 in the preparation of an anti-tumor medicament. | 04-14-2016 |
20160113931 | Method of treating and/or preventing neurodegenerative diseases - The present disclosure provides a method of treating and/or preventing neurodegenerative diseases, such as Parkinson disease, Alzheimer disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis, comprising administrating a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof to a subject in need thereof. | 04-28-2016 |
20160137651 | PYRAZOLOPYRIMIDINE COMPOUNDS - The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof. | 05-19-2016 |
20160159815 | Fused Piperidine Amides as Modulators of Ion Channels - The invention relates to fused piperidine amides useful as inhibitors of ion channels for the treatment of pain. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 06-09-2016 |
20160160205 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS - The present invention is directed to methods and compositions for activating a Parkin ligase by administering to a subject in need thereof a therapeutically effective amount of a compound that disrupts at least one Parkin ligase zinc finger. The present invention is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. | 06-09-2016 |
20160250216 | INHIBITION OF HIF-2ALPHA HETERODIMERIZATION WITH HIF1BETA (ARNT) | 09-01-2016 |
20180021342 | CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRI- MIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE | 01-25-2018 |
20190144456 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | 05-16-2019 |
20220133727 | COMBINATION THERAPIES FOR USE IN TREATING CANCER - The compound of Formula (I), or pharmaceutically acceptable salts thereof, is useful in, among other things, the treatment of MTAP-deficient lung cancer, such as NSCLC, or MTAP-deficient pancreatic cancer, such as PDAC, or MTAP-deficient esophageal cancer and provides a therapeutic advantage when used in combination with other agents as herein described compared to treatment with each agent when administered alone. | 05-05-2022 |
20220135567 | TYK2 PSEUDOKINASE LIGANDS - Described herein are TYK2 pseudokinase ligands and methods of utilizing TYK2 pseudokinase ligands in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds. | 05-05-2022 |
20220135576 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME - Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof. | 05-05-2022 |